Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market
Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price of Roche’s innovator Rituxan. The launch marks Teva's first biosimilar launch in the US.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker include a Neulasta biosimilar approval for Sandoz, novel approvals for Celgene's Reblozyl and Giskit B.V.'s ExEm Foam, and a submission for Regeneron's Ebola candidate.
Teva's business appears to be stabilizing but the company needs to resolve outstanding opioid liability litigation. CEO Schultz said he is hopeful a national settlement framework will be finalized.
Pfizer has received approval from the US Food and Drug Administration for the country’s second biosimilar rituximab, under the Ruxience label. However, the company has not yet revealed launch plans for the rival to Roche’s Rituxan brand.